Viral Serpin Reactive Center Loop (RCL) Peptides: Design and Testing

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Serpins act as suicide inhibitors of serine proteases by trapping them via their reactive center loop (RCL).
• Protease cleavage of the RCL results in a covalent linkage, inactivating both molecules in a mechanism termed 'suicide inhibition'.
• Serpinopathies arise from mutations causing abnormal serpin aggregation, where RCLs insert into adjacent serpins, leading to loss of function.

Purpose of the Study:

• To investigate the potential of active serpin metabolites formed at natural RCL cleavage sites.
• To develop and characterize reactive center loop (RCL)-derived peptides from myxomaviral serpins (Serp-1 and Serp-2).
• To assess the inhibitory functions of these novel RCL peptides in vitro and in vivo.

Main Methods:

• Peptide development based on predicted RCL cleavage sites of Serp-1 and Serp-2.
• In vitro molecular assays to evaluate peptide inhibitory functions.
• In vivo testing in models of cell migration, MHV-68 infection, and aortic allograft transplantation.

Main Results:

• Development of RCL-derived peptides from Serp-1 and Serp-2.
• Demonstration of peptide inhibitory functions through molecular assays.
• Evaluation of in vivo efficacy in various disease models, including infection and transplantation.

Conclusions:

• RCL-derived peptides represent a novel class of molecules with potential therapeutic applications.
• These peptides may offer new strategies for treating serpinopathies and other conditions involving protease dysregulation.
• Further research into RCL peptides could uncover additional inhibitory functions and broaden their therapeutic potential.